Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171746
Title: | Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study |
Author: | Sánchez Ortega, Isabel Parody, Rocío Grupo Español de Trasplante Hematopoyético (GETH) |
Keywords: | Morbiditat Mortalitat Cèl·lules mare Morbidity Mortality Stem cells |
Issue Date: | 1-Mar-2020 |
Publisher: | Nature Publishing Group |
Abstract: | Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41409-019-0731-x |
It is part of: | Bone Marrow Transplantation, 2020, vol. 55, num.3, p. 641-648 |
URI: | http://hdl.handle.net/2445/171746 |
Related resource: | https://doi.org/10.1038/s41409-019-0731-x |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
GomezVE.pdf | 930.05 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License